New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:15 EDTQCORQuestcor continues lower as FDA says reviewing Acthar lab test results
Shares of Questcor (QCOR) are down 3.8% in pre-market trading to $64.90 after falling 9% yesterday following Citron Research claiming the company's Acthar drug faces "severe risk" of being pulled from the market by the FDA. Following the Citron report, the FDA stated in an e-mail to Bloomberg that it had received a letter and lab results from an attorney as mentioned by Citron and was reviewing the materials. Questcor's COO Steve Cartt stated in an e-mail to Bloomberg First Word that "each Acthar lot meets FDA-mandated specifications which have not changed over several decades," the news service reported.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
13:13 EDTQCOREinhorn bought Lam Research shares, sold Rite Aid last quarter
Subscribe for More Information
12:18 EDTQCORGreenlight discloses short positions in Safeway, Questcor, Bloomberg says
Subscribe for More Information
10:02 EDTQCOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:22 EDTQCORQuestcor downgraded to Perform from Outperform at Oppenheimer
July 24, 2014
09:10 EDTQCORQuestcor expects insurance coverage for Acthar to remain favorable, consistent
Subscribe for More Information
09:10 EDTQCORQuestcor reports Q2 H.P. Acthar gel sales up 39% to $188.5M
Subscribe for More Information
09:10 EDTQCORQuestcor reports Q2 adjusted EPS $1.85, consensus $1.74
Subscribe for More Information
July 21, 2014
07:36 EDTQCORMallinckrodt price target raised to $95 from $85 at Jefferies
Subscribe for More Information
July 17, 2014
11:12 EDTQCOROptions with decreasing implied volatility
Subscribe for More Information
July 16, 2014
16:13 EDTQCORMallinckrodt initiated with an Outperform, $100 target at Oppenheimer
Oppenheimer believes Mallinckrodt's (MNK) acquisition of Questcor (QCOR) provides sustainable high-growth revenue potential. It believes the company bought Acthar at an attractive valuation. Opco started shares of Mallinckrodt with an Outperform rating and $100 price target.
10:35 EDTQCOROptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use